| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 01/01/2004 | US20040002109 Process for identifying modulators of G-protein-coupled receptors |
| 01/01/2004 | US20040002106 Enzymatic DNA molecules capable of cleaving RNA, referred to as the "Bipartite DNAzymes" capable of self-cleavage at an internal ribonucleotide |
| 01/01/2004 | US20040002104 Constant length signatures for parallel sequencing of polynucleotides |
| 01/01/2004 | US20040002103 Synthetic ligation reassembly in directed evolution |
| 01/01/2004 | US20040002100 Comprises assaying a suppressing effect of a test substance on an expression of a splicing variant transcribed from presenilin-2 gene |
| 01/01/2004 | US20040002099 Genes and genetic elements associated with sensitivity to platinum-based drugs |
| 01/01/2004 | US20040002098 Observing hybridization with fluorescence during and/or immediately after PCR and using this information for product identification, sequence alteration detection, and quantification; fluorescence resonance energy transfer (fret) |
| 01/01/2004 | US20040002094 Method to monitor the changes in comprehensive cellular gene expression levels at single length resolution by using a high-density microarray prepared with a comprehensive collection of ORFs (open reading frame) of a genome |
| 01/01/2004 | US20040002092 Hybrid and single chain meganucleases and use thereof |
| 01/01/2004 | US20040002088 Identification and isolation of novel DNA and to the recombinant production of polypeptides having sequence similarity to Glial Cell line-derived Neurotrophic Factor Receptor (GDNFR) |
| 01/01/2004 | US20040002087 Nucleic acid for detecting endocrine disrupting property of chemical substance, nucleic acid detecting probe and nucleic acid detecting primer containing the nucleic acid, probe-immobilized chip comprising the nucleic acid detecting probe, peptide derived from the nucleic acid and antibody recognizing the peptide, probe-immobilized chip comprising the antibody, and method of detecting endocrine disrupting property of chemical substance using them |
| 01/01/2004 | US20040002084 Identifying agents or compositions useful in the treatment of asthma or in methods for diagnosing or identifying eosinophil-related disorders in humans and mammals |
| 01/01/2004 | US20040002081 Uses a chromatographic separation process comprising a combination of two different chromatographic steps selected from hydrophobic interaction chromatography, polar interaction chromatography and anion exchange chromatography |
| 01/01/2004 | US20040002078 Arrays |
| 01/01/2004 | US20040002077 siRNA expression system and method for producing functional gene knock-down cell using the system |
| 01/01/2004 | US20040002076 Sequencing and performing polymerase reactions using an improved generation of nucleic acid polymerases; comprises fusion of a sequence-non-specific nucleic-acid-binding domain to the enzyme to enhances the processivity of the polymerase |
| 01/01/2004 | US20040002073 Multiplexed analysis of polymorphic loci by concurrent interrogation and enzyme-mediated detection |
| 01/01/2004 | US20040002071 Genetic analysis for stratification of cancer risk |
| 01/01/2004 | US20040002066 36 human secreted proteins |
| 01/01/2004 | US20040002065 Protein/solubility folding assessed by structural complementation |
| 01/01/2004 | US20040002062 Retrovirus-based genomic screening |
| 01/01/2004 | US20040002061 Methods of using the signal to transmit and maintain influenza viral and foreign nucleic acid in virus and cells |
| 01/01/2004 | US20040002060 For efficient targeting of adenoviral vectors; can be combined with other modifications, such as fiber knob and/or penton modifications, to produce fully ablated (detargeted) adenoviral vectors |
| 01/01/2004 | US20040002059 Screening method and a screening system capable of selecting agents capable of interfering with this protein-protein interaction; selection of agents capable of modulating this protein-protein interaction for treatment and control of PV |
| 01/01/2004 | US20040002057 Cloning vectors and methods for producing a library of DNA molecules capable of expressing a fusion polypeptide on the surface of a filamentous phage particle |
| 01/01/2004 | US20040002056 Used in methods of screening for candidate bioactive agents that produce an altered phenotype in the cells |
| 01/01/2004 | US20040002054 Associated with connective tissue diseases, progeroid disorders, and aging; methods for isolating such molecules; and the use of such molecules in human and veterinary practice |
| 01/01/2004 | US20040002053 Plant nitrogen regulatory P-PII genes |
| 01/01/2004 | US20040001904 Cellulose degrading enzymes of aspergillus |
| 01/01/2004 | US20040001867 Vectors for molecule delivery to CD11b expressing cells |
| 01/01/2004 | US20040001864 Using antigens; genetic enginering; gene expression of capsid; heat resistance |
| 01/01/2004 | US20040001854 Isolated, genetic engineered polypeptide |
| 01/01/2004 | US20040001850 Dna sequences; genetic engineering |
| 01/01/2004 | US20040001849 Antigen library immunization |
| 01/01/2004 | US20040001844 Lewis Y epitope-containing mucin fusion polypeptide vaccines, compositions and methods of use thereof |
| 01/01/2004 | US20040001841 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 01/01/2004 | US20040001840 Cancer-linked gene as target for chemotherapy |
| 01/01/2004 | US20040001832 Childhood obesity; antidiabetic agents; culture product; hybrid nucleic acid |
| 01/01/2004 | US20040001828 Treatment methods using anti-CD22 antibodies |
| 01/01/2004 | US20040001824 Cell proliferation inhibitors |
| 01/01/2004 | US20040001820 Polynucleotides; antiinflammatory agents; modulate immunologyresponse |
| 01/01/2004 | US20040001811 Compositions and methods for inhibiting expression of anti-apoptotic genes |
| 01/01/2004 | US20040001810 Administering dosage of nucleic acids; cardiovascular disorders |
| 01/01/2004 | US20040001805 Prevention infections; gene therapy; insertion of genome; genetic engineered vaccine |
| 01/01/2004 | US20040001802 Immobilized tumor necrosis factor |
| 01/01/2004 | US20040001790 Methods for diagnosis and treatment of tumours |
| 12/31/2003 | WO2004001506A2 Antireflective coatings for high-resolution photolithographic synthesis of dna array |
| 12/31/2003 | WO2004001424A1 Materials and methods for inductions of immune tolerance |
| 12/31/2003 | WO2004001423A1 Reporter module molecules having active ion channel activity |
| 12/31/2003 | WO2004001381A2 Novel raag10 cell surface target and a family of antibodies recognizing that target |
| 12/31/2003 | WO2004001376A2 Apparatus for polynucleotide detection and quantitation |
| 12/31/2003 | WO2004001371A2 Receptor capture assay |
| 12/31/2003 | WO2004001074A1 Method for detecting foreign dna in a host genome |
| 12/31/2003 | WO2004001073A1 Method and kit for the diagnosis of ulcerative colitis |
| 12/31/2003 | WO2004001072A2 Method for diagnosis of colorectal tumors |
| 12/31/2003 | WO2004001069A2 Compositions and methods for detecting pathologies affecting neuromuscular transmission |
| 12/31/2003 | WO2004001068A2 Use of pp2a phosphatase modulators in the treatment of mental disorders |
| 12/31/2003 | WO2004001065A2 Exhaustive selection or rna aptamers against complex targets |
| 12/31/2003 | WO2004001063A2 Methods and compositions for monitoring primer extension and polymorphism detection reactions |
| 12/31/2003 | WO2004001061A2 Antisense modulation of heme oxygenase 1 expression |
| 12/31/2003 | WO2004001056A1 Process for preparing g-csf |
| 12/31/2003 | WO2004001051A2 Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions |
| 12/31/2003 | WO2004001050A1 Plastidial targeting peptide |
| 12/31/2003 | WO2004001048A1 Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation |
| 12/31/2003 | WO2004001047A1 Novel promoter |
| 12/31/2003 | WO2004001046A1 Method of generating resistance against cucurbit yellow stunting disorder virus (cysdv) in plants, genetic constructions used and cysdv-resistant plants thus produced |
| 12/31/2003 | WO2004001045A1 Inhibition of nuclear receptors |
| 12/31/2003 | WO2004001044A1 Randomised dna libraries and double-stranded rna libraries, use and method of production thereof |
| 12/31/2003 | WO2004001042A2 Microarrays displaying encoded molecules |
| 12/31/2003 | WO2004001041A1 Expression vector, host, fused protein, process for producing fused protein and process for producing protein |
| 12/31/2003 | WO2004001040A1 Tissue-specific/environmental stress-specific promoter |
| 12/31/2003 | WO2004001039A1 Actinomyces-origin plasmid and process for producing secondary metabolite using the same |
| 12/31/2003 | WO2004001037A1 Method of diagnosing risk of myocardial infarction |
| 12/31/2003 | WO2004001036A1 Compositions and methods for selecting open reading frames |
| 12/31/2003 | WO2004001034A2 Regulation of gene expression using intron 1 of the ly-6 gene superfamily |
| 12/31/2003 | WO2004001032A2 Stable adenoviral vectors and methods for propagation thereof |
| 12/31/2003 | WO2004001031A1 Enzyme for decomposition of sulfated fucan derived from sea cucumber |
| 12/31/2003 | WO2004001028A1 Plant-derived transferase genes |
| 12/31/2003 | WO2004001027A1 Oligonucleotide inhibitors of mbd2/dna demethylase and uses thereof |
| 12/31/2003 | WO2004001026A1 Method of preparing recombinant mononegaviruses and the applications thereof |
| 12/31/2003 | WO2004001024A2 Genetically engineered keratinocytes expressing at least one growth factor and/or activated egf receptor, skin equivalent comprising said keratinocytes and toxicity assay using said keratinocytes |
| 12/31/2003 | WO2004001020A2 Methods and means to promote gut absorption |
| 12/31/2003 | WO2004001017A2 Methods for identifying antimicrobial agents, the agents identified therewith and methods of using same |
| 12/31/2003 | WO2004001013A2 Inhibition of gene expression in vertebrates using double-stranded rna (rnai) |
| 12/31/2003 | WO2004001012A2 Plant defensins |
| 12/31/2003 | WO2004001009A2 Apo-2 ligand/trail variants and uses thereof |
| 12/31/2003 | WO2004001004A2 Membrane associated tumor endothelium markers |
| 12/31/2003 | WO2004001003A2 Plastid division and related genes and proteins, and methods of use |
| 12/31/2003 | WO2004001001A2 Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids |
| 12/31/2003 | WO2004001000A2 Intron double stranded rna constructs and uses thereof |
| 12/31/2003 | WO2004000997A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 12/31/2003 | WO2004000994A2 Novel acetylcholinesterase gene responsible for insecticide resistance and applications thereof |
| 12/31/2003 | WO2004000883A1 Regulation of human growth hormone-releasing hormone receptor |
| 12/31/2003 | WO2004000882A2 Proteins |
| 12/31/2003 | WO2004000881A1 Dna sequence and recombinant production of the grass pollen allergen phl p4 |
| 12/31/2003 | WO2004000877A2 Peptides derived from the rabies virus glycoprotein g, ligands of the low-affinity receptor of neurotrophins (p75ntr) and applications thereof |
| 12/31/2003 | WO2004000876A1 INFECTIOUS cDNA OF AN APPROVED VACCINE STRAIN OF MEASLES VIRUS, USE FOR IMMUNOGENIC COMPOSITIONS |
| 12/31/2003 | WO2004000875A2 Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders |
| 12/31/2003 | WO2004000871A2 Thioesterase-related nucleic acid sequences and methods |
| 12/31/2003 | WO2004000369A2 Method of magnetically manipulating a cell with magnetisable particles |